InsiderTrades

Form 4 for TARS Tarsus Pharmaceuticals, Inc.

Accepted 2022-08-26 00:00:00 ET · period of report 2022-08-24 · accession 0001788542-22-000004 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2022-08-26 2022-08-24 TARS Mottiwala Aziz Chief Commercial Off M - OptEx $9.42 +5,188 55.8K +10% +$48.9K
DM 2022-08-26 2022-08-24 TARS Mottiwala Aziz Chief Commercial Off M - OptEx $9.42 -5,188 10.6K -33% -$48.9K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-08-24 M A 772 $0.45 56,586 D — —
2 Common Common Stock 2022-08-24 M A 4,416 $10.99 55,814 D — — (F1) Includes 470 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and includes 725 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022.
3 Derivative Employee Stock Option (right to buy) 2022-08-24 M D 772 $0.45 0 D $0.45 · — to 2028-09-13 772 Common Stock (F3) Option granted under the Plan. 25% of the option shares vested and became exercisable on July 27, 2019 and the remaining option shares vest and become exercisable in 36 equal monthly installments thereafter.
4 Derivative Employee Stock Option (right to buy) 2022-08-24 M D 4,416 $10.99 10,573 D $10.99 · — to 2030-09-24 4,416 Common Stock (F2) Option granted under the Tarsus Pharmaceuticals, Inc. 2016 Stock Plan (the "Plan"). The option shares vest and become exercisable in 48 equal monthly installments beginning on October 25, 2020.